Correction: treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes


This article was previously published with error in ‘Competing interests’ statement. The correct ‘Competing interests’ statement is mentioned below:

SC, NM, JH, AHS and HA declare no conflict of interest in relation to this manuscript. RC is a full time employee and shareholder of Opiant Pharmaceuticals. MS is part-time employee, board member and shareholder of Clinical Research Services Turku—CRST Oy, a clinical contract research organisation for the pharmaceutical industry. Previous research on nasal naloxone NALPET-study (EudraCT-number 2015-002681-23) by MS and HA have received grant support from Opiant Pharmaceuticals.